ADAPTIVE BIOTECHNOLOGIES CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.75 USD | +5.77% |
|
+9.56% | -43.88% |
Presenter SpeechJanet Dally;Maidstone Life Sciences LLC;Founder and Managing Director (Attende...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patientâs immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).
Calendar
2024-05-06
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
2.75
USD
Average target price
6.667
USD
Spread / Average Target
+142.42%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.88% | 405M | |
| -20.55% | 10.81B | |
| +47.97% | 3.36B | |
| -32.75% | 2.22B | |
| -14.15% | 2.16B | |
| -26.06% | 1.55B | |
| +19.85% | 1.04B | |
| -2.62% | 746M | |
| -31.67% | 425M | |
| +29.03% | 378M |
- Stock Market
- Equities
- ADPT Stock
- News Adaptive Biotechnologies Corporation
- Transcript : Adaptive Biotechnologies Corporation Presents at William Blair Biotech Focus Conference, Aug-05-2020 02
